The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy

Median survival benefit after IMT and surgery compared with IMT alone was 8 mo for patients who achieved PR. The resection of tumor residues after PR under IMT seems to extend the long-term survival of patients with mRCC and should be attempted when surgically feasible.